Inna Thalmann

Inna is Co-Founder and COO of Mable - a precision medicine company using whole genome sequencing to optimise prescribing decisions. Prior to this, Inna completed her PhD in Econometrics with a focus on Health Economics at the University of Oxford, followed by postdoctoral research focused on the development of novel phenotype algorithms to increase the cost-efficiency of clinical trials.